US Executive Officer Management Changes SEC — September 22, 2026

22-09-2026

Pentair plc appointed Robert W. Hau as Executive Vice President and Chief Financial Officer, effective November 1, 2026, succeeding Robert P. Fishman, who will resign as Interim CFO. Hau, 60, brings extensive CFO experience from Fiserv, TE Connectivity, Lennox, and Honeywell, and will receive a $775,000 base salary, a 100% bonus target, an initial equity award of $2,500,000, and a $200,000 cash bonus. The appointment is part of a planned leadership transition, with no financial results or operational changes disclosed.

• · Robert W. Hau previously served as CFO of Fiserv, Inc. from 2016 to 2025 and as Special Advisor from 2025 to March 31, 2026.
• · Hau's prior roles include EVP and CFO at TE Connectivity (2012-2016), EVP and CFO at Lennox International (2009-2012), and VP and CFO of Honeywell's aerospace business (2006-2009).
• · The $200,000 new hire cash bonus is subject to repayment if Hau voluntarily terminates employment within two years of hire.
• · Hau will be eligible for an annual equity incentive award beginning in 2027.
• · The KEESA provides for severance and benefits upon a change in control under certain conditions.
• · The appointment is effective November 1, 2026, with Fishman resigning at that time.

22-09-2026

Cypherpunk Technologies appointed Amanda Fabiano, a veteran mining executive, to its Board of Directors, effective September 22, 2026. The company also reported that its Cypherpunk Mining unit generated 3,023.13 ZEC in its first weeks of operation (August 18-31, 2026), with all rewards added to treasury. While the appointment and mining output are positive, the company faces significant risks including ZEC price volatility, network hashrate changes, and reliance on third-party custody and hosting services.

• · Fabiano currently serves as COO of Nakamoto Inc. and independent director of TeraWulf Inc.
• · Fabiano previously held senior mining and investment roles at Galaxy and Fidelity.
• · Mining fleet launched in August 2026 with approximately 4.2 GSol/s of hashrate.
• · Company's strategy includes mining Zcash, accumulating ZEC through open market purchases, and investing in privacy technologies.
• · Subsidiary Leap Therapeutics is developing sirexatamab and FL-501 for cancer patients.
• · Risks include ZEC price volatility, network hashrate changes, reliance on Gemini Space Station for custody/trading, and dependence on third-party hosting facilities.

22-09-2026

Central Garden & Pet Company announced the retirement of John D. Walker as President, Garden Consumer Products, effective September 26, 2026. The filing does not disclose a successor or any financial impact.

• · Retirement effective September 26, 2026.
• · No successor named in the filing.
• · Filing made under Item 5.02 (Departure of Directors or Certain Officers).

22-09-2026

Brunswick Corporation announced a leadership transition: CEO and Executive Chairman David Foulkes will retire at the end of 2026, with Aine Denari, currently EVP and President of Navico Group and CTO, appointed CEO effective January 1, 2027. David Everitt, Lead Independent Director, will become Non-Executive Chairman. The company highlighted strong momentum and a robust succession plan, but the announcement includes forward-looking risk factors and no financial results.

• · David Foulkes has served as CEO since January 2019 and Chairman since February 2025, with a two-decade career at Brunswick.
• · Aine Denari joined Brunswick in 2020 as EVP and President of Brunswick Boat Group.
• · Denari holds advanced degrees from Stanford, Northwestern, Purdue, University of Detroit Mercy, and University College Dublin.
• · Brunswick has more than 60 industry-leading brands.
• · The transition is effective January 1, 2027, with Foulkes retiring at the end of 2026.

22-09-2026

CNX Resources Corp announced the immediate departure of CFO Everett W. Good, effective September 17, 2026, with no disagreement related to operations, policies, or practices. Ravi Srivastava, previously Senior Vice President Operations, was appointed CFO and principal financial officer, while Melissa Long was named principal accounting officer. Mr. Good will receive a lump sum cash payment of $220,673.08, accelerated vesting of 24,701 time-based restricted stock units, and continued vesting of 39,033 performance-based equity awards, and will remain a non-executive employee until October 2, 2026, followed by a consulting role through end of 2026.

• · Mr. Good's departure was without cause and not due to any disagreement with the Company.
• · Mr. Good will remain a non-executive employee until October 2, 2026, then serve in a consulting capacity through end of 2026.
• · Mr. Srivastava joined the Company in 2010 and has held roles including President, New Technologies (Dec 2021) and VP Data and Operations Technology (June 2020).
• · Ms. Long has served as VP Financial Reporting and Controller since May 2026; previously Director of Accounting from January 2022.
• · Mr. Srivastava holds a bachelor's in electrical engineering from Bluefield State College, a master's in engineering management from Penn State, and an MBA from MIT.

22-09-2026

PetVivo Holdings, Inc. appointed Michael K. Handley to its Board of Directors effective September 22, 2026, filling the vacancy created by Joseph Jasper's resignation on the same date. Mr. Handley brings over 25 years of life sciences experience, having raised more than $700 million in capital and contributed to transactions exceeding $4 billion. The Board continues to consist of six directors following the change.

• · Michael Handley most recently served as CEO and director of Valion Bio, Inc.
• · He previously held CEO and chairman roles at Statera Biopharma, Inc., and CEO and director roles at Immune Therapeutics, Corp and Armis Biopharma.
• · He helped found Vessix Vascular, Inc. and served as VP of Clinical, Quality and Regulatory until its acquisition by Boston Scientific in 2012.
• · Handley graduated cum laude from Colorado State University with a B.S. in Molecular Biology and Physiology, attended the Executive MBA program at Pepperdine University, and completed the Global C-Suite Program at Wharton.
• · PetVivo's lead product SPRYNG® with OsteoCushion® technology is a veterinarian-administered intra-articular injection for lameness and osteoarthritis in cats, dogs, and horses.

22-09-2026

Capitol Federal Financial, Inc. (CFFN) announced the departure of Tara Van Houweling, Reporting Director and Principal Accounting Officer, effective October 9, 2026. Kent Townsend, Executive Vice President and Chief Financial Officer, will assume the role of Principal Accounting Officer. Ms. Van Houweling served the company for 23 years.

• · Departure effective date: October 9, 2026
• · Kent Townsend will serve as Principal Accounting Officer in addition to his CFO and Treasurer roles

22-09-2026

Vogenx, Inc. appointed Ken Toombs as an independent director and Audit Committee Chair, effective September 21, 2026. Mr. Toombs brings three decades of global professional services and life sciences leadership, including former CEO of PA Consulting. The appointment broadens independent oversight as the company scales operations following its August 2026 IPO.

• · Mizagliflozin is a first-in-class, orally administered, minimally absorbed SGLT1 inhibitor for PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome.
• · No FDA-approved therapeutics exist for PBH.
• · Toombs holds a B.S. in accounting from USC and an M.B.A. from Kellogg School of Management.
• · Toombs is based in the Research Triangle region of North Carolina.

22-09-2026

Associated Banc-Corp announced the retirement of EVP, General Counsel and Corporate Secretary Randall J. Erickson, effective October 13, 2026. He will serve as Attorney-Advisor through January 4, 2027, maintaining his base salary and benefits. The transition is orderly with no financial impact disclosed.

• · Mr. Erickson will remain in an advisory capacity through end of 2026.
• · He will continue to vest in unvested awards under 2025-2027 and 2026-2028 LTIPP.
• · He is eligible for full 2026 short-term incentive based on applicable metrics.

22-09-2026

On September 22, 2026, Quantum X Labs Inc. (formerly Viewbix Inc., trading as QXL) announced the departure of Co-CEO Amihay Hadad effective immediately, with no disagreement related to operations, policies, or practices. Co-CEO Yakov Baranes, who had served since May 2026, was appointed as the sole CEO. The filing does not include any financial data or period-over-period comparisons.

• · Mr. Hadad's departure was effective immediately on September 22, 2026.
• · Mr. Baranes had served as Co-CEO since May 2026 before being appointed sole CEO.
• · The company's common stock trades on the Nasdaq Capital Market under the symbol QXL.
• · The company is incorporated in Delaware with its principal office in Ramat Gan, Israel.

22-09-2026

On September 21, 2026, Dr. Sunggyu Lee notified Northern Technologies International Corporation (NTIC) that he will not stand for re-election to the Board of Directors at the 2027 Annual Meeting, currently scheduled for January 15, 2027. Dr. Lee's decision was not based on any disagreement with the company regarding operations, policies, or practices. This departure represents a change in board composition but does not indicate any underlying conflict or operational issue.

• · Dr. Lee's departure is not due to any disagreement with the company.
• · The 2027 Annual Meeting is currently scheduled for January 15, 2027.
• · The filing was signed by Matthew C. Wolsfeld, CFO and Corporate Secretary.

22-09-2026

Houlihan Lokey appointed Prabha Sipi Bhandari as Chief Legal Officer, effective September 22, 2026, succeeding Christopher Crain who served as General Counsel since 2004. Ms. Bhandari brings extensive experience from Paychex, AIG, Freddie Mac, Viacom, and Deutsche Bank. Mr. Crain will transition to Corporate Senior Advisor to assist with the leadership transition and advise on non-legal matters.

• · Ms. Bhandari will serve as corporate secretary to the board of directors and as an Executive Officer.
• · She spent 13 years at Deutsche Bank, serving as Managing Director, General Counsel for Deutsche Bank Securities Inc., and Global Head of M&A – Legal.
• · She began her legal career as a Law Clerk for the Honorable John M. Duhé Jr. of the Fifth Circuit U.S. Court of Appeals.
• · Mr. Crain served as General Counsel since 2004, over 22 years.

22-09-2026

United Parks & Resorts Inc. filed an 8-K on September 22, 2026, disclosing amendments to its Bylaws under Items 5.02 and 5.03. The amendments primarily update procedural rules for stockholder meetings, including advance notice requirements for director nominations and other business proposals, as well as provisions for remote meetings. The filing also indicates a director/officer departure or election, but no specific financial metrics or performance data are provided.

• · The Bylaws were amended and restated, effective as of the filing date.
• · New advance notice deadlines for stockholder proposals: notice must be delivered 90 to 120 days before the anniversary of the prior year's annual meeting.
• · If the meeting date is advanced by more than 30 days or delayed by more than 70 days, the notice window adjusts accordingly.
• · Stockholders nominating directors must provide detailed disclosures, including any compensation agreements, voting commitments, and compliance with corporate policies.
• · The Bylaws now explicitly allow the Board to postpone, reschedule, or cancel any annual or special meeting.
• · Remote-only meetings are permitted under Section 2.11 of the Bylaws.
• · Stockholders must update and supplement their notices as of the record date and 15 days before the meeting.
• · For nominations under Rule 14a-19, stockholders must deliver evidence of compliance with the rule no later than 5 business days before the meeting.

22-09-2026

SCYNEXIS appointed Steven K. Burke, M.D., a seasoned biopharma executive with over 30 years of experience and deep nephrology expertise, to its Board of Directors effective September 18, 2026. The appointment follows the company's acquisition of SCY-770, a Phase 2-ready AMPK activator for Autosomal Dominant Polycystic Kidney Disease (ADPKD), which the company describes as a transformative year. The filing is a routine board appointment announcement with no negative financial metrics to report.

• · Dr. Burke has served as Senior Vice President, Chief Research and Development Officer and Chief Medical Officer at Akebia Therapeutics since 2021.
• · SCY-770 has been granted Orphan Drug Designation by the FDA for the treatment of ADPKD.
• · SCY-770 has been evaluated in several Phase 1 trials and one Phase 2a trial in NAFLD patients.
• · SCYNEXIS's antifungal platform includes BREXAFEMME, licensed to GSK, and SCY-247 in clinical development.

22-09-2026

Fiserv Inc. announced the resignation of Adam L. Rosman as Chief Administrative Officer and Chief Legal Officer, effective September 30, 2026. Eric C. Nelson, the current General Counsel and Secretary, will succeed him as Chief Legal Officer on October 1, 2026. The filing contains no financial results or period-over-period comparisons.

• · Resignation effective date: September 30, 2026
• · Succession date: October 1, 2026
• · Eric C. Nelson will become Chief Legal Officer

22-09-2026

Upbound Group, Inc. appointed Scott Young as Chief Operating Officer (a newly created role to unify Acima, Brigit, and Rent-A-Center) and Dev Chakraborty as Senior Vice President and Head of Brigit. The company highlighted Brigit's annual recurring revenue of approximately $300 million and 1.8 million paying users. No financial performance comparisons were provided in the filing beyond these forward-looking statements.

• · Scott Young most recently served as SVP and Global Head of Financial Solutions at PayPal and Venmo.
• · Dev Chakraborty previously served as General Manager of Cards, Mortgages and Data Partnerships at MoneyLion and General Manager of Personal Loans at Credit Karma.

22-09-2026

Madison Square Garden Sports Corp. (MSGS) announced executive role changes effective September 21, 2026. Jamaal T. Lesane transitioned from Chief Operating Officer to Executive Vice President and Chief Legal Officer, while Bryan Warner ceased to be an executive officer but remains employed as Senior Vice President, Head of Legal. The filing contains no financial data or performance metrics.

• · Jamaal T. Lesane ceased to serve as Chief Operating Officer effective September 21, 2026.
• · Bryan Warner is no longer an executive officer but continues in his role as Senior Vice President, Head of Legal under his existing employment agreement.

22-09-2026

Piper Sandler Companies (NYSE: PIPR) announced the election of Wendy L. Schoppert to its board of directors, effective September 22, 2026. Ms. Schoppert brings extensive experience as a former CFO of Sleep Number Corporation and current board roles at DaVita Inc. and Fossil Group, Inc. The filing contains no financial results or period-over-period comparisons, so no quantitative performance data is available.

• · Wendy L. Schoppert previously served as EVP and CFO of Sleep Number Corporation (2011-2014), SVP and CIO (2008-2011), and SVP and GM of international and new channel development (2005-2008).
• · She began her career in the airline industry with roles at America West Airlines, Northwest Airlines, and American Airlines.
• · She holds a bachelor's degree in mathematics and operations research and an MBA, both from Cornell University.

22-09-2026

On September 18, 2026, FDCTech, Inc. expanded its Board from four to six directors and conditionally appointed two new directors, Jeff M. Pies and Dena Lauren Decker, effective upon the company's common stock being approved for listing on a National Exchange (Nasdaq or NYSE). The appointments are subject to conditions, including the company obtaining D&O insurance by October 18, 2026, which has not yet been bound. The company also entered into Director Agreements and D&O Side Letters with each designee, outlining compensation and other terms.

• · The Director Agreements become effective on the Effective Date, but certain provisions (indemnification, insurance, confidentiality) were effective upon signing.
• · Each Director Designee may terminate their Director Agreement if the Company fails to obtain required D&O insurance.
• · The Company has not yet bound the required D&O insurance as of the filing date.
• · The Board has not yet determined committee assignments for the Director Designees; an amendment will be filed within four business days after determination.
• · The Company's common stock is not currently listed on a National Exchange, and there is no assurance of listing approval.
• · The Director Agreements include a review period during which a Director Designee may decline appointment or resign without penalty.
• · Neither Director Designee has a family relationship with any director or executive officer, nor a material interest in any transaction requiring disclosure under Item 404(a).
• · The appointments are conditional and will become effective only upon listing approval, with a deadline of September 18, 2028 (or later if agreed in writing).

22-09-2026

Curtiss-Wright announced a planned leadership transition: COO Kevin M. Rayment will become President and CEO effective January 1, 2027, succeeding Lynn M. Bamford, who will retire as CEO and become Executive Chair after six years in the role. The company highlighted record financial performance under Bamford, including $1.7 billion returned to shareholders, while noting the transition is part of a planned succession process. No negative or declining metrics were reported.

• · Kevin Rayment has served as COO since 2021 and joined Curtiss-Wright in 2004.
• · Bamford's tenure as CEO lasted six years.
• · Rayment holds a BEng (Hons) in Electrical & Electronics Engineering from Portsmouth University and an MBA from Bournemouth University.
• · The company operates in Aerospace & Defense, Commercial Nuclear Power, Process and Industrial markets.

22-09-2026

Old Dominion Freight Line announced the immediate retirement of board member John D. Kasarda, Ph.D., effective September 22, 2026, with no disagreement with the company. The board elected Worthing F. Jackman as an independent director, appointing him to the Governance and Nomination and Talent and Compensation Committees. Mr. Jackman, former CEO of Waste Connections, will receive a pro rata portion of the $110,000 annual cash retainer and a $172,000 restricted stock award.

• · Mr. Jackman, 62, served as CEO of Waste Connections from July 2019 to April 2023, and previously as CFO from September 2004 to July 2018.
• · Mr. Jackman is Chairman of the Audit Committee and a member of the Finance and Investment Committee at Quanta Services, Inc. (NYSE: PWR).
• · Mr. Jackman serves as Executive Chair of the board of WillScot Holdings Corporation (NASDAQ: WSC).
• · Mr. Jackman has no family relationships with company officers and no material interest in any transaction requiring disclosure under Item 404(a).

22-09-2026

Federal Home Loan Bank of Des Moines announced the departure of Kevin Larkin as Chief Information and Operations Officer, effective September 18, 2026. The separation was initiated by the Bank. No successor or interim arrangement was disclosed in the filing.

• · The filing does not disclose a reason for the departure or a replacement plan.
• · The effective date of separation is September 18, 2026, the same day the Bank notified Mr. Larkin.

22-09-2026

GE HealthCare appointed Pascal Desroches, CFO of AT&T, to its Board of Directors effective January 4, 2027. Mr. Desroches brings over 30 years of finance, governance, and digital transformation experience, including roles at AT&T, WarnerMedia, Turner Broadcasting, KPMG, and the SEC. The appointment strengthens the board as the company executes its precision care strategy.

• · Mr. Desroches plans to retire from AT&T on December 31, 2026, before joining the GE HealthCare board on January 4, 2027.
• · He chairs the audit committee at Honeywell Aerospace and serves on the board of the Federal Reserve Bank of Dallas.
• · He previously served on the board of DaVita for nearly four years, bringing healthcare governance experience.
• · GE HealthCare was named among the 2026 Fortune World's Most Admired Companies.

22-09-2026

ECB Bancorp, Inc. appointed Matthew J. Cushing as a director of the Company and its wholly owned subsidiary, Everett Co-operative Bank, effective September 16, 2026. Mr. Cushing will serve until the 2027 annual meeting and will also join the Audit Committee. He will participate in the standard non-employee director compensation program. No material transactions or arrangements were disclosed in connection with his appointment.

• · Mr. Cushing's term expires at the 2027 annual meeting of shareholders.
• · He was appointed to the Audit Committee of both the Company and the Bank.
• · No arrangements or understandings exist with any person regarding his selection as director.
• · No transactions requiring disclosure under Item 404(a) of Regulation S-K were reported.

22-09-2026

Helmerich & Payne, Inc. announced compensation increases for its President & CEO Trey Adams and CFO Todd Scruggs, effective October 1, 2026. CEO base salary rises to $1,000,000 with target bonus at 130% of salary and long-term equity at 500% of salary for fiscal 2027. CFO base salary increases to $570,000 with target bonus at 100% of salary. No negative or flat metrics are present in this filing.

• · Compensation changes were ratified by the Board on September 16, 2026, following approval by the Human Resources Committee.
• · CEO base salary increase is effective October 1, 2026.
• · CEO target bonus increased to 130% of base salary for fiscal 2027.
• · CEO target long-term equity incentive award increased to 500% of base salary for fiscal 2027.
• · CFO base salary increase to $570,000 effective October 1, 2026.
• · CFO target bonus increased to 100% of base salary for fiscal 2027.